Gubra A/S

Equities

GUBRA

DK0062266474

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 10:59:35 2024-05-08 am EDT			5-day change	1st Jan Change
338 ^DKK	-2.87%		+11.55%	+170.40%

Apr. 17	Gubra Unveils UCN2 as Novel Anti-Obesity Drug Candidate for Healthy Weight Loss	CI
Mar. 29	Certain Shares of Gubra A/S are subject to a Lock-Up Agreement Ending on 29-MAR-2024.	CI

Gubra Concludes the Research Agreement with Silence Therapeutics plc

January 26, 2024 at 07:33 am EST

Gubra announced the finalization of its two-year explorative research agreement with Silence Therapeutics PLC that was signed in early 2022. The collaboration concerned early target discovery of RNAi therapies for liver diseases. In collaboration with Silence Therapeutics, the company have explored potential novel liver-targets for diseases with an unmet medical need.

The company has had a great collaboration with Silence Therapeutics and both parties have completed the planned activities according to the research plan. The company jointly decided not to further pursue any research activities under this collaboration and consequently Gubra does not expect future income from this collaboration.

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	GUBRA A/S	338 DKK	-2.87%	+11.55%	793M
	SILENCE THERAPEUTICS PLC	22.84 USD	+1.06%	+7.37%	1.05B

Latest news about Gubra A/S

Gubra Unveils UCN2 as Novel Anti-Obesity Drug Candidate for Healthy Weight Loss	Apr. 17	CI
Certain Shares of Gubra A/S are subject to a Lock-Up Agreement Ending on 29-MAR-2024.	Mar. 28	CI
Gubra Concludes the Research Agreement with Silence Therapeutics plc	Jan. 26	CI
Gubra and Boehringer Ingelheim Sign 4Th Partnership, Expanding Their Successful Obesity Treatment Discovery Collaboration	Dec. 13	CI
Gubra A/S Announces First Subject Dosed in Phase 1 Clinical Trial of Amylin Agonist for the Treatment of Obesity	Nov. 29	CI
Gubra A/S Announces Board Appointments	Nov. 01	CI
Gubra Raises Earnings Guidance for Full-Year 2023	23-10-26	CI
Denmark's Gubra Opens First US Office Under Expansion Strategy	23-10-24	MT
Gubra A/S Opens Its First US Office in Boston	23-10-24	CI
Gubra Seeks UK Regulatory Approval to Begin Human Trial for Anti-Obesity Drug	23-09-06	MT
Gubra A/S Submits Clinical Trial Application for First-In-Human Amylin Trial	23-09-06	CI
Tranche Update on Gubra A/S's Equity Buyback Plan announced on June 30, 2023.	23-08-25	CI
Gubra Announces Termination of Collaboration with Bayer AG	23-08-23	CI
Gubra A/S Raises Financial Guidance for Full-Year 2023	23-08-15	CI
Gubra A/S commences an Equity Buyback Plan for 1,180,424 shares, under the authorization approved on March 16, 2023.	23-06-30	CI
Gubra A/S acquired Minigut Aps for DKK 5.96 million.	23-06-28	CI
Gubra A/S Announces Updates to Its Pipeline	23-06-09	CI
Gubra A/S and Boehringer Ingelheim Share Phase 1 Results for BI 1820237	23-05-17	CI
Gubra A/S Provides Revenue Guidance for the Year 2023	23-05-11	CI
Danish Biotech Gubra's IPO Overallotment Option Partly Exercised	23-05-02	MT
Gubra A/S(CPSE:GUBRA) added to OMX Nordic All-Share Index	23-04-10	CI
Gubra A/S has completed an IPO in the amount of DKK 500.00005 million.	23-03-30	CI
Gubra A/S has filed an IPO in the amount of DKK 500.00005 million.	23-03-20	CI

Chart Gubra A/S

Duration

Period

More charts

Company Profile

Gubra A/S is a Denmark-based biotechnology company specialized in high-end pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases. The Companyâs operations are anchored around its advanced technology platforms and utilization of automation, robotization and digitalization, including machine learning (ML) and artificial intelligence (AI). The Company's business activity are divided into two segments: The CRO Segment offers specialized profitable pre-clinical contract research services at attractive margins within metabolic and fibrotic disease areas such as diabetes, obesity, chronic kidney disease; and The Discovery and Partnership Segment is based on an internal target and drug discovery engine for identification and design of peptide-based drug partnering candidates within metabolic and fibrotic diseases.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
GUBRA A/S	+170.40%	793M
VERTEX PHARMACEUTICALS INCORPORATED	+3.18%	108B
REGENERON PHARMACEUTICALS, INC.	+10.32%	105B
ARGENX SE	+1.57%	23.46B
BIONTECH SE	-13.05%	21.72B
GENMAB A/S	-7.05%	18.64B
WUXI APPTEC CO., LTD.	-37.64%	17.45B
BEIGENE, LTD.	-6.89%	17.19B
NEUROCRINE BIOSCIENCES, INC.	+5.78%	13.99B
SAREPTA THERAPEUTICS, INC.	+36.43%	12.53B

Bio Therapeutic Drugs